Novartis' Kisqali Reduces Breast Cancer Recurrence by Nearly One-Third, Trials Show
By Adam Whittaker
Novartis said that its Kisqali drug reduces the risk of breast cancer recurrence by nearly one-third, in updated analysis from Phase 3 trials.
The Swiss pharmaceutical company said Monday that its Kisqali drug shows benefits beyond the three-year treatment period, reducing the risk of recurrence by 28.5% in patients with early breast cancer.
The results show its safety is in line with previously reported results, with recipients showing generally low-grade symptomatic adverse events, reinforcing its well-tolerated profile, the company said.
The results are being presented on Monday at the European Society for Medical Oncology (ESMO) Congress 2024.
Regulatory reviews are underway, with the U.S. Food and Drug Administration set to take regulatory action in the third quarter of this year, the company said.
Write to Adam Whittaker at adam.whittaker@wsj.com
(END) Dow Jones Newswires
September 16, 2024 04:57 ET (08:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks